Last patient enrolled in study evaluating the efficacy of MODIA in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
UPPSALA, Sweden, Oct. 28, 2022. Orexo AB (publ.), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA as part of a clinician supervised medication-assisted treatment program for the treatment of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Information Technology | Pharmaceuticals | Study | Suboxone | Sweden Health